– USA, TX – OncoNano Medicine, Inc. today announced the appointment of Dr. Brett Giroir (M.D.) to its Board of Directors.
“It is my pleasure to welcome Dr. Giroir to our Board and work with him as we advance our differentiated technology platform for the development of novel interventions and treatments for cancer patients. Brett’s wealth of experience and expertise in clinical practice, public health and entrepreneurial enterprises will be instrumental as we enter a pivotal stage for the growth of our company,” saidCEO, Martin Driscoll.
About Dr. Brett Giroir
Dr. Giroir is a physician-scientist and innovator, whose career has been dedicated to improving public health and medicine. Formerly, he served as the 16th Assistant Secretary for Health in the U.S. Department of Health and Human Services, Acting FDA Commissioner, and Admiral in the U.S. Public Health Service Commissioned Corps. Dr. Giroir also served as the U.S. Representative to the Executive Board of the World Health Organization within the Department of State and was on the front lines of the COVID-19 response as a member of the White House Task Force and the national lead for testing and diagnostics. Dr. Giroir is a graduate of Harvard University and the University of Texas Health Science Center, where he served on the faculty for ten years.
“I am excited to assist in the development and commercialization of OncoNano’s novel platform technology, which has the realistic potential to revolutionize targeting of tumors with anti-cancer therapies and cancer imaging agents,” said Dr. Giroir. “I look forward to working with OncoNano’s outstanding team and world-renowned scientific founders to advance this broadly applicable anti-cancer technology for the benefit of patients with unmet medical needs.”
About OncoNano Medicine
OncoNano Medicine is developing a new class of products that exploit pH as a biomarker to diagnose and treat cancer with high specificity. Our product candidates are designed to help patients across the continuum of cancer care and include solid tumor therapeutics, agents for real-time image-guided surgery, and a platform of product candidates that activate and guide the body’s immune system to target cancer.
For more information: https://www.onconano.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
